Vimian Group (VIMIAN.ST) Stock Analysis & AI Equity Report
Vimian Group (VIMIAN.ST) overview
Vimian Group (VIMIAN.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Vimian Group reported revenue of EUR 425m and operating profit of EUR 73.6m; the year-end share price was 30.34 SEK and market capitalisation was SEK 15,950m. Vimian Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vimian Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Vimian Group
Vimian Group is a global animal health company focused on four areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. It develops and sells products and services for companion animal and livestock care, including veterinary treatments, orthopedic and dental products, clinic services, and molecular and immunodiagnostic solutions, supported by international distribution and in-house development.
Generate the Vimian Group report
Vimian Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Vimian Group and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.